Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder marked by erythematous pustules and desquamation on the palms and soles. While IL-17 pathways are implicated in PPP, IL-17 blockers have shown modest efficacy, underscoring the need for a deeper understanding of IL-17 involvement. To dissect the cellular and spatial architecture of PPP, we performed single-cell RNA-Seq (scRNA-Seq) on lesional, nonlesional, and healthy acral skin to examine cellular composition, transcriptomic profiles, and cell-cell interactions. Unbiased clustering revealed 9 major cell types, including an inflammatory keratinocyte subset enriched in IL-17A/TNF signatures and marked by high IL-36G expression. Within the lymphocyte compartment, we identified a hybrid "regTh17" population coexpressing regulatory markers (FOXP3, CTLA4, TIGIT), IL17F, and IL26. This regTh17 subset was distinguished by elevated IL1R1 and CD39, suggesting an IL-1β-driven differentiation. Spatial analyses demonstrated significant neighborhood enrichment of regTh17 cells with IL-36G+ supraspinous keratinocytes. RegTh17 cells were the predominant source of IL-17F and IL-26 signals, whereas keratinocytes were predicted as their main receivers. We further observed regTh17 coexpressing TNFRSF4 (OX40) and TNFRSF18 (GITR) specifically at sites of IL36G+ keratinocyte interactions, implicating these pathways in amplification of the IL-17/IL-36 inflammatory loop. Together, our integrated single-cell and spatial profiling uncovers Th17 plasticity in PPP, identifies a regTh17-keratinocyte interaction, and highlights IL-17F, IL-26, OX40/OX40L, and GITR/GITRL as candidate targets for precision therapies in this challenging disease.
Authors
- Mio Nakamura (ORCID: https://orcid.org/0000-0002-1367-742X)
- Olesya Plazyo (ORCID: https://orcid.org/0000-0002-6859-7590)
- Paul W. Harms (ORCID: https://orcid.org/0000-0002-0802-2883)
- Mehrnaz Gharaee‐Kermani (ORCID: https://orcid.org/0000-0002-2177-2427)
- Robert L. Modlin (ORCID: https://orcid.org/0000-0003-4720-031X)
- Lam C. Tsoi (ORCID: https://orcid.org/0000-0003-1627-5722)
- H. Tran (ORCID: https://orcid.org/0000-0002-2191-5483)
- Johann Eli Gudjonsson (ORCID: https://orcid.org/0000-0002-0080-0812)
- Joanne Michelle Kahlenberg (ORCID: https://orcid.org/0000-0002-4006-8945)
- Michel Gilliet (ORCID: https://orcid.org/0000-0002-4609-3762)
- Rundong Jiang (ORCID: https://orcid.org/0000-0002-9217-0749)
- Xianying Xing (ORCID: https://orcid.org/0000-0003-4227-6868)
- Özge Uluçkan (ORCID: https://orcid.org/0000-0001-9468-1211)
- Jennifer Fox
- Enze Xing (ORCID: https://orcid.org/0000-0001-9358-9368)
- Allison C. Billi (ORCID: https://orcid.org/0000-0001-7115-9113)
- Rachael Bogle (ORCID: https://orcid.org/0000-0003-3544-3023)
- Haihan Zhang (ORCID: https://orcid.org/0000-0002-5902-7289)
- Madalina Raducu
Institutions
- University of California, Los Angeles (US)
- University of Michigan (US)
- UCLA Health (US)
- UCLA Medical Center (US)
- A. Alfred Taubman Health Care Center (US)
- Almirall (Spain) (ES)
- University of Lausanne (CH)
Publication Details
- Journal
- JCI Insight
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1172/jci.insight.193038
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Biogen
- University of Michigan
- Regeneron Pharmaceuticals
- Argenx
- Galderma
- National Institutes of Health
- EMD Serono
- College of Pharmacy, University of Michigan